5-112840513-G-T
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP3_Moderate
The NM_000038.6(APC):c.4919G>T(p.Arg1640Leu) variant causes a missense change. The variant allele was found at a frequency of 0.00000137 in 1,461,862 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R1640W) has been classified as Likely benign.
Frequency
Consequence
NM_000038.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
APC | NM_000038.6 | c.4919G>T | p.Arg1640Leu | missense_variant | 16/16 | ENST00000257430.9 | NP_000029.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
APC | ENST00000257430.9 | c.4919G>T | p.Arg1640Leu | missense_variant | 16/16 | 5 | NM_000038.6 | ENSP00000257430 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461862Hom.: 0 Cov.: 66 AF XY: 0.00 AC XY: 0AN XY: 727230
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Familial adenomatous polyposis 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 13, 2021 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with APC-related conditions. ClinVar contains an entry for this variant (Variation ID: 825288). This variant is not present in population databases (ExAC no frequency). This sequence change replaces arginine with leucine at codon 1640 of the APC protein (p.Arg1640Leu). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and leucine. - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 26, 2018 | The p.R1640L variant (also known as c.4919G>T), located in coding exon 15 of the APC gene, results from a G to T substitution at nucleotide position 4919. The arginine at codon 1640 is replaced by leucine, an amino acid with dissimilar properties. A different alteration at this position, p.R1640Q, was reported in an individual with early onset colorectal cancer; however, it was also reported in a cohort of 681 ancestrally diverse, healthy subjects (Pearlman R et al. JAMA Oncol. 2017 Apr;3:464-471; Bodian DL et al. PLoS ONE. 2014 Apr;9:e94554). In addition, p.R1640W (designated as 1841Arg>Trp) was reported in a familial adenomatous polyposis (FAP) kindred and segregated with disease in multiple affected family members; however, the presence of a gross deletion in APC was not ruled out in these samples (Stella A et al. Hum Mol Genet. 1994 Sep;3(9):1687-8). More recently, p.R1640W was detected in conjunction with a second missense variant in a FAP patient, but no familial testing to determine segregation with disease was performed (Scott R et al. Hered Cancer Clin Pract. 2004;2(2):81-91). This amino acid position is highly conserved in available vertebrate species. In addition, p.R1640L is predicted to be probably damaging and deleterious by PolyPhen and SIFT in silico analyses, respectively. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at